Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 3/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | GRIN2B | Q13224 | 2/20 | 0.37 |
| ▸ | REV1 | Q9UBZ9 | 1/20 | 0.37 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.37 |
| ▸ | DRD4 | P21917 | 2/20 | 0.35 |
| ▸ | TSHR | P16473 | 2/20 | 0.35 |
| ▸ | LMNA | P02545 | 2/20 | 0.35 |
| ▸ | USP2 | O75604 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4021974 | 1.00 | MEN1 (0.42) | MEN1KMT2AALDH1A1GAAGRIN2B | |
| SCHEMBL4028145 | 0.89 | MEN1 (0.38) | MEN1KMT2AALDH1A1GAAGRIN2B | |
| SCHEMBL4028188 | 0.89 | MEN1 (0.38) | MEN1KMT2AALDH1A1GAAGRIN2B | |
| SCHEMBL4028149 | 0.89 | MEN1 (0.38) | MEN1KMT2AALDH1A1GAAGRIN2B | |
| SCHEMBL4022953 | 0.87 | ALDH1A1 (0.39) | MEN1KMT2AALDH1A1GAAGRIN2B | |
| SCHEMBL4022948 | 0.87 | ALDH1A1 (0.39) | MEN1KMT2AALDH1A1GAAGRIN2B | |
| SCHEMBL4026452 | 0.85 | ALDH1A1 (0.40) | MEN1KMT2AALDH1A1GAAGRIN2B | |
| SCHEMBL4028159 | 0.84 | ALDH1A1 (0.39) | MEN1KMT2AALDH1A1GAAGRIN2B | |
| SCHEMBL4019455 | 0.83 | DRD4 (0.37) | MEN1KMT2AALDH1A1GRIN2BDRD4 | |
| SCHEMBL4019453 | 0.83 | DRD4 (0.37) | MEN1KMT2AALDH1A1GRIN2BDRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7572814-B2 | 3,5-dibenzoyl-4-phenyl-piperidine anti-cancer compounds | CYTOKINETICS, INCORPORATED (US) | 2009-08-11 | — | — | US | claimed |
| US-7572814-B2 | 3,5-dibenzoyl-4-phenyl-piperidine anti-cancer compounds | CYTOKINETICS, INCORPORATED (US) | 2009-08-11 | — | — | US | disclosed |
| US-20070161674-A1 | Certain chemical entities, compositions, and methods | CYTOKINETICS, INC. | 2007-07-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070161674-A1 | Certain chemical entities, compositions, and methods | TP53, VHL, RB1 | MEN1 77/4885KMT2A 2820/4885ALDH1A1 258/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.